SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Launched by UNIVERSITY OF PALERMO · Jun 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients who are hospitalized due to acute heart failure, a condition where the heart doesn't pump blood as well as it should. The study will test a combination of high doses of a medication called furosemide, which helps the body get rid of excess fluid, along with a special saline solution and a type of diabetes medication known as an SGLT-2 inhibitor. The goal is to see if this combination can help patients lose weight quickly, reduce the time they spend in the hospital, and improve their ability to get rid of extra fluid without harming their kidneys.

To be eligible for the trial, participants must have acute heart failure and type 2 diabetes. However, those with certain conditions, like severe kidney problems or other serious heart issues, won't be able to join. If you qualify and choose to participate, you will be monitored closely during the treatment to assess how well the combination works for you. This trial is not yet recruiting participants, but it aims to provide valuable insights into better managing heart failure in patients with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • acute heart failure;
• • diabetes type 2.
• Exclusion Criteria:
• • low estimated glomerular filtration rate;
• • hypernatremia;
• • diabetes type 1;
• • non-cardiac causes of dyspnea;
• • cardiogenic shock;
• • recent occurrence of Acute Coronary Syndrome;
• • ketoacidosis;
• • hyperosmolar hyperglycemic syndrome.